421 related articles for article (PubMed ID: 35803084)
1. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K
Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
Yeo T; Siew RWE; Gulam MY; Tye JSN; Aw AYY; Sivalingam T; Peng X; Yong KP; Saffari SE; Chao Y; Tan K
J Neurol; 2023 Jun; 270(6):2817-2825. PubMed ID: 37027019
[TBL] [Abstract][Full Text] [Related]
3. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.
Dinoto A; Sechi E; Ferrari S; Gajofatto A; Orlandi R; Solla P; Maccabeo A; Maniscalco GT; Andreone V; Sartori A; Manganotti P; Rasia S; Capra R; Mancinelli CR; Mariotto S
Mult Scler Relat Disord; 2022 Feb; 58():103424. PubMed ID: 35216793
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.
Kim S; Seok HY
Neurol Sci; 2023 Jun; 44(6):1841-1848. PubMed ID: 36781562
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
Redenbaugh V; Flanagan EP
Neurotherapeutics; 2022 Apr; 19(3):808-822. PubMed ID: 35267170
[TBL] [Abstract][Full Text] [Related]
6. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
[TBL] [Abstract][Full Text] [Related]
7. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
[TBL] [Abstract][Full Text] [Related]
8. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
9. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
[TBL] [Abstract][Full Text] [Related]
10. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.
Li EC; Zheng Y; Cai MT; Lai QL; Fang GL; Du BQ; Shen CH; Zhang YX; Wu LJ; Ding MP
Epilepsia; 2022 Sep; 63(9):2173-2191. PubMed ID: 35652436
[TBL] [Abstract][Full Text] [Related]
11. Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience.
Monte G; Papetti L; Ferilli MAN; Ursitti F; Moavero R; Sforza G; Panella E; Tarantino S; Checchi MP; Vigevano F; Palma P; Valeriani M
Front Immunol; 2023; 14():1106472. PubMed ID: 36761740
[TBL] [Abstract][Full Text] [Related]
12. Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
Ciotti JR; Eby NS; Brier MR; Wu GF; Chahin S; Cross AH; Naismith RT
Mult Scler; 2022 Jan; 28(1):49-60. PubMed ID: 33870786
[TBL] [Abstract][Full Text] [Related]
13. Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?
Paybast S; Emami A; Baghalha F; Naser Moghadasi A
Mult Scler Relat Disord; 2022 Sep; 65():103960. PubMed ID: 35763914
[TBL] [Abstract][Full Text] [Related]
14. The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Sen S; Tuncer A; Ozakbas S; Uzunkopru C; Baba C; Demir S; Beckmann Y; Gumus H; Arslan G; Kilic AK; Altintas A; Yuceyar N; Turan OF; Tutuncu M; Terzi M; Acar P; Bunul SD; Balci BP; Bir LS; Koseoglu M; Mungan S; Gunduz T; Dogan IG; Kotan D; Uygunoglu U; Ekmekci O; Demirkiran M; Kamisli O; Kabay SC; Tamam Y; Omerhoca S; Sevim S; Guler S; Kurtuncu M; Efendi H; Karabudak R; Siva A
Mult Scler Relat Disord; 2022 Feb; 58():103399. PubMed ID: 35216782
[TBL] [Abstract][Full Text] [Related]
15. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
16. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
Messina S; Mariano R; Roca-Fernandez A; Cavey A; Jurynczyk M; Leite MI; Calabrese M; Jenkinson M; Palace J
Mult Scler; 2022 Feb; 28(2):217-227. PubMed ID: 34048323
[TBL] [Abstract][Full Text] [Related]
17. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
Cortese R; Prados Carrasco F; Tur C; Bianchi A; Brownlee W; De Angelis F; De La Paz I; Grussu F; Haider L; Jacob A; Kanber B; Magnollay L; Nicholas RS; Trip A; Yiannakas M; Toosy AT; Hacohen Y; Barkhof F; Ciccarelli O
Neurology; 2023 Jan; 100(3):e308-e323. PubMed ID: 36192175
[TBL] [Abstract][Full Text] [Related]
18. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
[TBL] [Abstract][Full Text] [Related]
19. Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination.
Francis AG; Elhadd K; Camera V; Ferreira Dos Santos M; Rocchi C; Adib-Samii P; Athwal B; Attfield K; Barritt A; Craner M; Fisniku L; Iversen AKN; Leach O; Matthews L; Redmond I; O'Riordan J; Scalfari A; Tanasescu R; Wren D; Huda S; Leite MI; Fugger L; Palace J
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411077
[TBL] [Abstract][Full Text] [Related]
20. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
